Joep J. de Jong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joep J. de Jong has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Necchi
Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy
18 shared publications - Ewan A. Gibb
Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
17 shared publications - Roland Seiler
Institute of Sport Science, University of Bern, Bern, Switzerland
17 shared publications - Elai Davicioni
Veracyte, Inc., South San Francisco, California
16 shared publications - Peter C. Black
Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
16 shared publications - Yair Lotan
Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA
16 shared publications
Latest Publications
- 6 November 2026
- Published by Elsevier in European Urology
Re: Can Aydogdu, Laura Bukavina, Liang Cheng, et al. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.05.030
- 6 November 2026
- Published by Elsevier in European Urology
Re: Can Aydogdu, Laura Bukavina, Liang Cheng, et al. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.05.030
- 31 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (21) , JCO2600142-2028
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial
PURPOSE: To evaluate neoadjuvant sacituzumab govitecan (SG), followed by radical cystectomy (RC), in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for/refuse neoadjuvant chemotherapy (NAC). We report the results of the primary analysis and biomarker analyses of the phase II SURE-01 trial (ClinicalTrials.gov identifier: NCT05226117 ). PATIENTS AND METHODS: Patients were age 18 years and older, had Eastern Cooperative Oncology Group performance status 0-1, had histologically confirmed cT2-T4aN0M0 MIBC, were ineligible/refusing NAC, and were scheduled for RC received four cycles of SG 10 mg/kg on day 1 and day 8, once every 3 weeks, followed by RC. The primary outcome measure was the pathologic complete response (pT0N0) rate. Transcriptome-wide analyses and comprehensive genomic profiling assays were performed on baseline tumor samples. RESULTS: From March 2022 to July 2025, 44 patients were treated and efficacy evaluable. After the initial eight patients enrolled, the protocol was amended with a SG dose of 7.5 mg/kg, with primary prophylaxis for neutropenia, due to the occurrence of two deaths (one treatment-related). Subsequent grade 3-4 treatment-related adverse-events occurred in 5 patients (13.9%). Twenty-six patients (59.1%) had a cT3-4 stage and 20 (45.5%) had a variant histology. Fourteen patients (31.8%) refused to undergo RC, accounting for 12 repeating a transurethral resection of the bladder tumor and two undergoing active surveillance. The median follow-up was 22 months (IQR, 15-26). In the intention-to-treat population, although the protocol-defined ypT0N0 rate was 9.1% (95% CI, 2.5 to 21.7), the overall ypT0N0-x rate was 29.5% (95% CI, 16.7 to 45.2), with an enrichment of ypT0 responses in nonluminal subtypes (46% v 14% of luminal). The 24-month event-free survival (EFS) rate was 71.4% (95% CI, 58 to 87.8), with longer EFS for participants with lower TOP1-expressing tumors. CONCLUSION: Neoadjuvant SG, at the reduced dose of 7.5 mg/kg, was active with a manageable safety profile, corroborating TROP2 as a suitable target for MIBC.
- 31 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (21) , JCO2600142-2028
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial
PURPOSE: To evaluate neoadjuvant sacituzumab govitecan (SG), followed by radical cystectomy (RC), in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for/refuse neoadjuvant chemotherapy (NAC). We report the results of the primary analysis and biomarker analyses of the phase II SURE-01 trial (ClinicalTrials.gov identifier: NCT05226117 ). PATIENTS AND METHODS: Patients were age 18 years and older, had Eastern Cooperative Oncology Group performance status 0-1, had histologically confirmed cT2-T4aN0M0 MIBC, were ineligible/refusing NAC, and were scheduled for RC received four cycles of SG 10 mg/kg on day 1 and day 8, once every 3 weeks, followed by RC. The primary outcome measure was the pathologic complete response (pT0N0) rate. Transcriptome-wide analyses and comprehensive genomic profiling assays were performed on baseline tumor samples. RESULTS: From March 2022 to July 2025, 44 patients were treated and efficacy evaluable. After the initial eight patients enrolled, the protocol was amended with a SG dose of 7.5 mg/kg, with primary prophylaxis for neutropenia, due to the occurrence of two deaths (one treatment-related). Subsequent grade 3-4 treatment-related adverse-events occurred in 5 patients (13.9%). Twenty-six patients (59.1%) had a cT3-4 stage and 20 (45.5%) had a variant histology. Fourteen patients (31.8%) refused to undergo RC, accounting for 12 repeating a transurethral resection of the bladder tumor and two undergoing active surveillance. The median follow-up was 22 months (IQR, 15-26). In the intention-to-treat population, although the protocol-defined ypT0N0 rate was 9.1% (95% CI, 2.5 to 21.7), the overall ypT0N0-x rate was 29.5% (95% CI, 16.7 to 45.2), with an enrichment of ypT0 responses in nonluminal subtypes (46% v 14% of luminal). The 24-month event-free survival (EFS) rate was 71.4% (95% CI, 58 to 87.8), with longer EFS for participants with lower TOP1-expressing tumors. CONCLUSION: Neoadjuvant SG, at the reduced dose of 7.5 mg/kg, was active with a manageable safety profile, corroborating TROP2 as a suitable target for MIBC.
- Open Access
- 23 May 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (2)
Proceedings of the first international NMIBC consensus classification meeting
Non–muscle invasive bladder cancer (NMIBC) is a biologically and clinically heterogeneous disease, accounting for approximately 75% of bladder cancer cases. Over the past decade, multiple RNA-based molecular classification systems for NMIBC have been proposed, demonstrating associations with tumor stage, grade, prognosis, and treatment response. However, unlike muscle-invasive bladder cancer, a unified consensus classification for NMIBC is lacking, limiting clinical translation and cross-study comparability. To address this gap, the first NMIBC Consensus Classification Meeting was convened in November 2024 at Erasmus University Medical Center, bringing together 13 international experts from seven countries representing major NMIBC molecular classification efforts. This report summarizes the discussions, comparative evaluation of existing classification systems, and the agreed strategy towards developing a consensus molecular model. The meeting focused on harmonizing heterogeneous transcriptomic datasets, integrating RNA sequencing and microarray platforms, and assessing the applicability of classification models across tumor stages (Ta/T1) and grades. Key features, strengths, and limitations of the Lund Taxonomy, Leeds, Birmingham, UROMOL, and Rotterdam (BCG response) subtypes were critically examined. Building on prior experience from the muscle-invasive bladder cancer consensus, participants agreed on a centroid-based clustering framework using rigorously defined core samples to derive stable consensus subtypes and a single-sample classifier with associated probability scores. A large, curated dataset encompassing approximately 2500 NMIBC samples from published cohorts will facilitate model development and validation. The resulting consensus classification aims to improve biological understanding, facilitate reproducibility across studies, and enable future evaluation of prognostic and therapeutic relevance, including response to intravesical BCG therapy.
- 23 May 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (2)
Open AccessProceedings of the first international NMIBC consensus classification meeting
Non–muscle invasive bladder cancer (NMIBC) is a biologically and clinically heterogeneous disease, accounting for approximately 75% of bladder cancer cases. Over the past decade, multiple RNA-based molecular classification systems for NMIBC have been proposed, demonstrating associations with tumor stage, grade, prognosis, and treatment response. However, unlike muscle-invasive bladder cancer, a unified consensus classification for NMIBC is lacking, limiting clinical translation and cross-study comparability. To address this gap, the first NMIBC Consensus Classification Meeting was convened in November 2024 at Erasmus University Medical Center, bringing together 13 international experts from seven countries representing major NMIBC molecular classification efforts. This report summarizes the discussions, comparative evaluation of existing classification systems, and the agreed strategy towards developing a consensus molecular model. The meeting focused on harmonizing heterogeneous transcriptomic datasets, integrating RNA sequencing and microarray platforms, and assessing the applicability of classification models across tumor stages (Ta/T1) and grades. Key features, strengths, and limitations of the Lund Taxonomy, Leeds, Birmingham, UROMOL, and Rotterdam (BCG response) subtypes were critically examined. Building on prior experience from the muscle-invasive bladder cancer consensus, participants agreed on a centroid-based clustering framework using rigorously defined core samples to derive stable consensus subtypes and a single-sample classifier with associated probability scores. A large, curated dataset encompassing approximately 2500 NMIBC samples from published cohorts will facilitate model development and validation. The resulting consensus classification aims to improve biological understanding, facilitate reproducibility across studies, and enable future evaluation of prognostic and therapeutic relevance, including response to intravesical BCG therapy.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S4. Twelve of the thirteen 13 scar-like cases previously identified in pembrolizumab-treated tumors (panel A) classified as stroma-rich by the consensus subtyping model, representing a subgroup with improved clinical outcomes (panel B)
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S4. Twelve of the thirteen 13 scar-like cases previously identified in pembrolizumab-treated tumors (panel A) classified as stroma-rich by the consensus subtyping model, representing a subgroup with improved clinical outcomes (panel B)
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S2. Defining novel biological clusters using gene expression profiling in radical cystectomy samples previously treated with neoadjuvant atezolizumab. Signature scores among ABACUS CC1-4 for (A) TGF-beta, (B) FGFR3 pathway, (C) Angiogenesis, (D) DNA repair, (E) Glycolysis, and (F) Apoptosis.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S2. Defining novel biological clusters using gene expression profiling in radical cystectomy samples previously treated with neoadjuvant atezolizumab. Signature scores among ABACUS CC1-4 for (A) TGF-beta, (B) FGFR3 pathway, (C) Angiogenesis, (D) DNA repair, (E) Glycolysis, and (F) Apoptosis.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S7. ESTIMATE tumor purity scores for the ABACUS cohort, stratified by LumP, LumNS, LumU, Basal-Sq, NE-like, and Stroma-rich vs Scar-like and the former tumor bed.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S7. ESTIMATE tumor purity scores for the ABACUS cohort, stratified by LumP, LumNS, LumU, Basal-Sq, NE-like, and Stroma-rich vs Scar-like and the former tumor bed.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S1. Disease Free Survival Outcomes for N = 84 TURBT cases from the ABACUS trial subtyped by Lund (A), Consensus (B) and TCGA (C) subtyping models.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S1. Disease Free Survival Outcomes for N = 84 TURBT cases from the ABACUS trial subtyped by Lund (A), Consensus (B) and TCGA (C) subtyping models.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S5. Differential gene expression analysis comparing the CC-scar-like to the remaining Consensus stroma-rich tumors. Select downregulated genes have been circled in blue.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S5. Differential gene expression analysis comparing the CC-scar-like to the remaining Consensus stroma-rich tumors. Select downregulated genes have been circled in blue.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Table S1: Input gene list of the n = 39 gene features included in the scar-like transcriptomic classifier.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Table S1: Input gene list of the n = 39 gene features included in the scar-like transcriptomic classifier.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S8. Comparing quantitative immunohistochemistry (IHC) scores between scar-like cases identified by the transcriptomic classifier (TC) and remaining samples from the ABACUS cohort.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy
Figure S8. Comparing quantitative immunohistochemistry (IHC) scores between scar-like cases identified by the transcriptomic classifier (TC) and remaining samples from the ABACUS cohort.